The DAYBREAK success de-risks the Zenkuda BLA submission due by year-end, but the rapid cash burn and thin equity base ($12.6M) mean the company will likely need additional capital before reaching profitability. Watch for the KSI-101 PEAK readout in December 2026 as the next major catalyst.
Drugs in focus
KOD drug pipeline →KSI-101
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- If Phase 3 PEAK succeeds, a BLA submission would follow. The company expects Pivotal Analysis 2 data in Q2 2027, suggesting a potential BLA filing in 2027 and potential approval in 2028, though no official timeline has been given.
- Next catalyst
- None dated
What to watchThe December 2026 PEAK topline data is the key binary event to watch. If KSI-101 replicates the Phase 1b APEX signal (meaningful vision gains, rapid retinal drying) in the larger Phase 3 setting, it would validate the bispecific IL-6/VEGF approach and strengthen Kodiak's pipeline beyond Zenkuda. A miss or underwhelming result would be a significant negative given the elevated stock price and stretched cash position. The company's thin equity base ($12.6 million) and ~$66 million quarterly burn rate mean financing risk is high regardless of the readout outcome.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $111.19entry
- T+1 · 15h ago −9.41%α −7.50% · $100.73
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kodiak Sciences reported Q3 2026 results with a net loss of $66.2M ($1.05/share), wider than the $61.5M loss in Q3 2025. The key positive was confirming that both Zenkuda and KSI-501 (tabirafusp-ted) met their primary endpoints in the Phase 3 DAYBREAK study, and the company is on track for a multi-indication BLA submission for Zenkuda by year-end and KSI-101 PEAK data in December 2026. Cash burn remains high, with cash dropping to $88.7M at quarter-end, partially offset by $69M in ATM proceeds raised after the quarter.
Key Financial Metrics
Key Facts
- Zenkuda met the DAYBREAK primary endpoint (p=0.0007) with 54% of patients on 6-month dosing
- Tabirafusp-ted (KSI-501) met DAYBREAK vision primary (p=0.0036) and anatomical key secondary (p<0.0001)
- Multi-indication BLA for Zenkuda planned for Q4 2026
- KSI-101 PEAK Pivotal Analysis 1 topline data expected December 2026
- Q3 2026 net loss $66.2M vs $61.5M in Q3 2025
- Cash and equivalents $88.7M at September 30, 2026
- Raised $69M net proceeds from ATM after quarter end
- Working capital $38.1M at September 30, 2026 vs $169.3M at December 31, 2025
- Stockholders' equity $12.6M at September 30, 2026 vs $157.4M at December 31, 2025
Financial Impact
Q3 2026 net loss of $66.2M, cash burn of $121.2M in 9 months; $69M raised post-quarter via ATM
Risk Factors
- Cash runway limited: $88.7M at quarter-end plus $69M ATM proceeds may not support operations into 2027 as stated, given $66M+ quarterly burn
- Stockholders' equity of only $12.6M raises going concern risk if additional financing is not secured
- BLA approval for Zenkuda is not guaranteed despite positive Phase 3 data
- KSI-101 PEAK results in December 2026 are a binary catalyst with significant upside/downside
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-458248 |
| Document: kod-20261112.htm | 0001193125-26-458248 |
| Document: 0001193125-26-458248-index-headers.html | 0001193125-26-458248 |
| Document: 0001193125-26-458248-index.html | 0001193125-26-458248 |
| Document: 0001193125-26-458248.txt | 0001193125-26-458248 |
| 8-K Data (Synthetic) | 0001193125-26-458248 |
Track record
13 reports on KOD
4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +17.99% at T+20 after the Jun 11, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $104.93 Now $100.73 +4.00% settles Dec 15
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $109.50 Now $100.73 +8.01% settles Dec 15
- Nov 12, 20264d ago 8-K Bullish 6/10 Viewing Entry $111.19 Now $100.73 −9.41% settles Dec 14
- Nov 6, 202610d ago Insider Buy Bullish 5/10 Entry $107.10 Now $100.73 −5.95% settles Dec 8
- Oct 20, 202627d ago S-3ASR Bearish 5/10 Entry $87.72 Now $100.73 −14.83% settles Nov 18
- Sep 30, 20266w ago SC 13D/A Bullish 7/10 Entry $98.46 to $100.40 Now $100.73 +2.31% ▲ +1.97% +1.27% vs SPY
- Sep 30, 20266w ago Insider Buy Bullish 5/10 Entry $98.46 to $100.40 Now $100.73 +2.31% ▲ +1.97% +1.27% vs SPY
- Sep 28, 20267w ago 8-K Bullish 7/10 Entry $89.92 to $89.60 Now $100.73 +12.02% ▼ −0.36% −0.32% vs SPY
- Aug 13, 202613w ago 8-K Neutral 4/10 No price data
- Aug 13, 202613w ago Press Release Neutral 6/10 Entry $41.35 to $33.14 Now $100.73 +143.60% ▼ −19.85% −17.86% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers